The emerging role of precision medicine in the treatment of endometrial cancer

IF 1 Q4 PHARMACOLOGY & PHARMACY

Expert Review of Precision Medicine and Drug Development Pub Date : 2020-02-20 DOI:10.1080/23808993.2020.1732204

M. Toboni, D. Mutch

{"title":"The emerging role of precision medicine in the treatment of endometrial cancer","authors":"M. Toboni, D. Mutch","doi":"10.1080/23808993.2020.1732204","DOIUrl":null,"url":null,"abstract":"ABSTRACT Introduction: Uterine cancer is the most common gynecologic malignancy with a high cure rate for early stage disease. Surgical and standard chemotherapy have provided modest results. Precision therapies targeting molecular pathways have recently produced encouraging results. Areas covered: This paper describes molecular pathways including PI3 K/AKT/mTor, VEGF, and angiogenesis, HER2/neu and EGFR, various endocrine therapies (including megace, medroxyprogesterone acetate, tamoxifen, letrozole, and anastrozole) and immune checkpoint inhibitors. An extensive literature search was completed including but not limited to PubMed, Google Scholar, and the studies conducted by the Gynecologic Oncology Group (GOG), to identify all relevant clinical trials opened to assess clinical benefit in patients with advanced endometrial cancer. Expert commentary: Molecular characterization of tumors provides an opportunity to tailor therapy to individual patients. With continual innovation, eventually real-time changes in treatment regimens can be made for individual patients to treat the ever-changing molecular landscape of the tumor. Immunotherapy remains the most promising treatment for advanced endometrial cancers.","PeriodicalId":12124,"journal":{"name":"Expert Review of Precision Medicine and Drug Development","volume":"5 1","pages":"87 - 93"},"PeriodicalIF":1.0000,"publicationDate":"2020-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23808993.2020.1732204","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Precision Medicine and Drug Development","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/23808993.2020.1732204","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 2

Abstract

ABSTRACT Introduction: Uterine cancer is the most common gynecologic malignancy with a high cure rate for early stage disease. Surgical and standard chemotherapy have provided modest results. Precision therapies targeting molecular pathways have recently produced encouraging results. Areas covered: This paper describes molecular pathways including PI3 K/AKT/mTor, VEGF, and angiogenesis, HER2/neu and EGFR, various endocrine therapies (including megace, medroxyprogesterone acetate, tamoxifen, letrozole, and anastrozole) and immune checkpoint inhibitors. An extensive literature search was completed including but not limited to PubMed, Google Scholar, and the studies conducted by the Gynecologic Oncology Group (GOG), to identify all relevant clinical trials opened to assess clinical benefit in patients with advanced endometrial cancer. Expert commentary: Molecular characterization of tumors provides an opportunity to tailor therapy to individual patients. With continual innovation, eventually real-time changes in treatment regimens can be made for individual patients to treat the ever-changing molecular landscape of the tumor. Immunotherapy remains the most promising treatment for advanced endometrial cancers.

查看原文本刊更多论文

精准医疗在子宫内膜癌症治疗中的新作用

摘要简介:子宫癌是妇科最常见的恶性肿瘤，早期治愈率高。手术和标准化疗的效果一般。针对分子途径的精确治疗最近产生了令人鼓舞的结果。涉及领域:本文描述了分子通路，包括pi3k /AKT/mTor, VEGF和血管生成，HER2/neu和EGFR，各种内分泌疗法(包括megace，醋酸甲孕酮，他莫昔芬，来曲唑和阿那曲唑)和免疫检查点抑制剂。我们完成了广泛的文献检索，包括但不限于PubMed、b谷歌Scholar和妇科肿瘤组(GOG)进行的研究，以确定所有相关的临床试验，以评估晚期子宫内膜癌患者的临床获益。专家评论:肿瘤的分子特征提供了一个机会，量身定制治疗的个别患者。随着不断的创新，最终可以为个体患者实时改变治疗方案，以治疗不断变化的肿瘤分子景观。免疫疗法仍然是晚期子宫内膜癌最有希望的治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Precision Medicine and Drug Development PHARMACOLOGY & PHARMACY-

CiteScore

2.30

自引率

0.00%

发文量

期刊介绍： Expert Review of Precision Medicine and Drug Development publishes primarily review articles covering the development and clinical application of medicine to be used in a personalized therapy setting; in addition, the journal also publishes original research and commentary-style articles. In an era where medicine is recognizing that a one-size-fits-all approach is not always appropriate, it has become necessary to identify patients responsive to treatments and treat patient populations using a tailored approach. Areas covered include: Development and application of drugs targeted to specific genotypes and populations, as well as advanced diagnostic technologies and significant biomarkers that aid in this. Clinical trials and case studies within personalized therapy and drug development. Screening, prediction and prevention of disease, prediction of adverse events, treatment monitoring, effects of metabolomics and microbiomics on treatment. Secondary population research, genome-wide association studies, disease–gene association studies, personal genome technologies. Ethical and cost–benefit issues, the impact to healthcare and business infrastructure, and regulatory issues.